The FDA has accelerated its review of Novartis’ sickle cell drug crizanlizumab after the company filed phase 2 results showing its effectiveness as a treatment for life threatening and pain
Another Alzheimer’s disease drug has been axed after Novartis, Amgen and the Banner Alzheimer’s Institute decided to end two pivotal studies involving a medicine targeting BACE.
Under threat from a gene therapy from Novartis, Biogen is making the case for its drug Spinraza for the muscle wasting disease spinal muscular atrophy, with new data that it hopes persuades
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
